PharmaTelevision - Merck Research Laboratories: David Nicholson explains Merck`s focus on early stage science space

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Merck Research Laboratories: David Nicholson explains Merck`s focus on early stage science space

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to David Nicholson, Senior Vice President and Head Worldwide Licensing and Knowledge Management of Merck Research Laboratories

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Merck Research Laboratories' role and responsibilities within Merck

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO 2011 in Washington DC. On this show I have David Nicholson, who is Senior Vice President of Licensing and Knowledge Management at Merck , welcome to the show.

David Nicholson:

Good morning, it's great to be here.

Fintan Walton:

Your role is as I've already mentioned Licensing and Knowledge Management, could you just tell us a little bit about where you fit within the Merck organization particularly as part of that process by which people do deals?

David Nicholson:

Yes of course, so at Merck we split licensing and business development up into two groups, I take care of the licensing organization licensing sits firmly and squarely within our R&D organization Merck Research Labs. The business development organization fits within the finance group and the business development group takes care of negotiations and the financial side of the transaction. Licensing takes care of the science side, Merck we all say it all starts with the science so first of all we do a scientific evaluation have a potential collaboration interaction if we see there is a good scientific fit we get our business development colleagues on board and we work as a team to complete the negotiation discussions and doing the deal.

Fintan Walton:

Okay excellent. Just a little bit on the Knowledge Management side what's that specific responsibility?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

David Nicholson

Head

David Nicholson currently serves as Senior Vice President Worldwide Licensing and Knowledge Management at Merck Research Laboratories. Dr. David Nicholson graduated in pharmacology, earning his B.S. from the University of Manchester and his Ph.D. from the University of Wales. He has been employed in research and development in the pharmaceutical industry since 1978. David began working for Beecham at its research facility in Germany in 1978. In 1988, he joined Organon BioSciences in Newhouse, Scotland, where he was the pharmacology department head. From 1993-2002, he worked in Organon's Oss, Netherlands, headquarters. During that time, he held the positions of program vice president of CV and CNS R&D (cardiovascular and central nervous system research and development); head of research in the Netherlands; head of global research; and, eventually, head of research and development for the company. Based in New Jersey since 2002, David joined Schering-Plough following its acquisition of Organon in 2007. Prior to his arrival at Merck in 2009, he served as senior vice president of Global Project Management and Drug Safety.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Merck Research Laboratories

Merck Research Laboratories discovers and develops medicines for cancer and neurodegenerative disorders. The company was founded in 2004 and is based in Boston, Massachusetts. Merck Research Laboratories operates as a subsidiary of Merck & Co Inc.